Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model

Journal of Veterinary Medical Science

Masanori ITAKURA²  Kazuhiro NISHIYAMA²  Tadayoshi TAKEUCHI²  Tomoko KOHDA¹  Takeya KUBO²  Hidemitsu NAKAJIMA²  Yuko SEMI²  Shunji KOZAKI¹  Yasu-Taka AZUMA² 

[1] Laboratory of Veterinary Epidemiology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1�?58 Rinku Ourai Kita, Izumisano-shi, Osaka 598�?8531, Japan;Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1�?58 Rinku Ourai Kita, Izumisano-shi, Osaka 598�?8531, Japan

关键词: adverse effect;    botulinum neurotoxin;    Parkinson’s disease;    rat;    subtype;   

DOI  :  10.1292/jvms.14-0184

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

References(24)Cited-By(1)Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1.

【 授权许可】

Unknown